Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.

Think PH1 Logo

AN OVERVIEW OF PRIMARY HYPEROXALURIA TYPE 1

Primary hyperoxaluria type 1 (PH1) is a rare, progressive, inherited metabolic stone disease that is potentially life-threatening, and often presents with kidney stones.1-3

PH1 IS A RARE, PROGRESSIVE, INHERITED METABOLIC STONE DISEASE1-3

Primary hyperoxaluria (PH) is a group of autosomal-recessive metabolic stone diseases resulting from defects in different enzymes involved in glyoxylate metabolism that lead to an overproduction of oxalate in the liver.2,3 There are 3 types of PH: PH1, PH2, and PH3, each of which is caused by a defect in a different enzyme.3

PH1 often presents with kidney stones and is caused by autosomal recessive mutations in the AGXT gene, which impairs the function of the liver-specific enzyme alanine:glyoxylate aminotransferase (AGT).1,3 Normally, AGT processes glyoxylate, which is generated by another liver enzyme, glycolate oxidase (GO).2,3

EARLIER DIAGNOSIS OF PH1 MAY HELP MITIGATE KIDNEY DAMAGE2-6

PH1 is the most common—and most severe—type of PH1,3,7

70%-80% of PH cases are PH1. Even so, PH1 is a rare disease, affecting an estimated 1 to 3 cases per million population, and incidence rate of 1 case per 120,000 live births per year in Europe, with higher prevalence in the Middle East and North Africa region.1,3,7

PH1 can result in irreparable kidney damage1,3

One of the most devastating aspects of PH1 is that it causes a progressive decline in kidney function, culminating in end-stage kidney disease (ESKD).1,3,6 Moreover, there is the potential risk of systemic oxalosis.3

Early diagnosis and intervention are key to mitigating damage2-6

Management approaches may lessen damage by reducing stone formation and kidney deposition of calcium oxalate crystals; this underscores the importance of early diagnosis and intervention.3,7

PH1 IS PROGRESSIVE AND SYSTEMIC2,9

See how PH1 can be life-threatening2

Play Video about PH1 Mechanism of Disease Video Thumbnail

PH1 leads to progressive decline in kidney function.2

EXCESS OXALATE CAN DAMAGE THE KIDNEYS9

Liver oxalate overproduction may lead to inflammation and progressive kidney function decline following calcium oxalate crystal formation.9 Continuous oxalate overproduction may lead to irreversible damage in the kidneys and other organs.9

PH1 advances at variable rates, progressing to ESKD.2 When the kidneys are unable to excrete oxalate effectively due to toxicity from calcium oxalate crystal deposition, systemic oxalosis—the widespread tissue deposition of calcium oxalate—can occur.9 Complications from systemic oxalosis can be fatal.2

In some instances, kidney function can decline after a single incident of dehydration due to acute illness or intense physical activity.10–13 This can occur even in patients with previously stable disease.9,11

WHAT CAUSES OXALATE OVERPRODUCTION IN PH1?

Inability of AGT to process glyoxylate made by GO2

PH1 is a genetic disease caused by mutations in the AGXT gene that renders the liver enzyme AGT dysfunctional.3

Normally, AGT processes glyoxylate, which is generated by another liver enzyme, GO.2,3 In PH1, a defect in AGT means glyoxylate is instead converted to oxalate.2 Oxalate cannot be metabolised and is typically excreted by the kidneys at normal levels.3 When overproduced as it is in PH1, oxalate can wreak progressive, irreversible damage.2 Oxalate combines with calcium, creating calcium oxalate crystals.2 These crystals attach to kidney tissues, where they can aggregate to form kidney stones or lead to nephrocalcinosis.2,9 As calcium oxalate accumulates, kidney excretion is impaired, and crystals deposit throughout the body.9

Download an overview of PH1

PH1 HCP Brochure
Kim Hollander - Executive Director - Oxalosis and Hyperoxaluria Foundation
“Given the nature of this disease, PH1 can go undiagnosed for many years. Early symptoms in adults, such as kidney stones, are often attributed to other, much more common conditions. We need to help physicians recognise symptoms faster, to stop progression before a patient reaches end-stage renal failure.”

Kim Hollander

Testing patients for PH1

See how genetic testing plays an important role in a PH1 diagnosis.2,4

Get Updates

Sign up to receive information from Alnylam about PH1

References: 1. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 2. Milliner DS, Harris PC, Cogal AG, Lieske JC. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated November 30, 2017. Accessed October 2023. 3. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 4. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736. 5. Ben-Shalom E, Frishberg Y. Pediatr Nephrol. 2015;30(10):1781-1791. 6. Raju DL, Cantarovich M, Brisson ML, Tchervenkov J, Lipman ML. Am J Kidney Dis. 2008;51(1):e1-e5. 7. Bhasin B, Ürekli HM, Atta MG. World J Nephrol. 2015;4(2):235-244. 8. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271. 9. Leumann E, Hoppe B. J Am Soc Nephrol. 2001;12(9):1986-1993. 10. El-Reshaid K, Al-Bader D, Madda JP. Saudi J Kidney Dis Transpl. 2016;27(3):606-609. 11. Cochat P. Kidney Int. 1999;55(6):2533-2547. 12. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Int J Nephrol. 2011;2011:864580. 13. Tintillier M, Pochet JM, Cosyns JP, Delgrange E, Donckier J. Clin Nephrol. 2004;62(2):155-157.

PH1-CEMEA-00126 | November 2023

Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.

Welcome to the ThinkPH1.eu Healthcare Professional website.

By accessing the website, you confirm to be a Healthcare Professional from Europe, Middle East, or Africa:

If you are not a Healthcare Professional, please access the LivingwithPH1.eu website here.

You are now leaving ThinkPH1

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.